Despite shared AKT and ERK signaling in FLT3 and CXCR4 downstream pathways, BM stroma-mediated resistance to quizartinib in FLT3-ITD-AML was mediated through persistent activation of ERK, not AKT, consistent with a previous report under different co-culture conditions [21]. The gene discussed is FLT3; the disease is acute myeloid leukemia.